BIOMAT Database Logo BIOMAT Database Logo

Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. 1998

P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
Clinical Pharmacology Unit, EA 643 University Claude Bernard, Hôpital Cardiologique, Lyon, France. PG@upcl.univ-lyon1.fr

This study establishes a population PK model for FVII clotting activity (FVII:C) after injection of recombinant activated factor VII (rFVIIa) to healthy volunteers. Twenty eight volunteers, anticoagulated with acenocoumarol, received one or two rFVIIa injections, with dose ranging from 5 to 320 microg/kg. The FVII:C kinetic was fitted to a 2 compartment model, with continuous "endogenous perfusion" mimicking endogenous activity. Estimated clearance was 2.4 1/h (20% inter-individual variability and 9% inter-period variability). The volume of distribution at steady-state appeared to be significantly dose dependent: 78 ml/kg for doses < or = 20 microg/kg and 88 ml/kg for doses > 20 microg/kg respectively, with 16% inter-individual variability. The dose producing 50% of the maximum drop of INR was estimated to be 2.2 microg/kg. The model will be used to better define the dosage regimen for future clinical developments.

UI MeSH Term Description Entries
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074 Acenocoumarol A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233) Acenocoumarin,Nicoumalone,Mini-Sintrom,Sinkumar,Sinthrome,Sintrom,Syncoumar,Syncumar,Synthrom,Mini Sintrom,MiniSintrom
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D015942 Factor VIIa Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation. Coagulation Factor VIIa,Factor VII, Activated,Blood Coagulation Factor VII, Activated,Factor 7A,Factor Seven A,Activated Factor VII,Factor VIIa, Coagulation
D016015 Logistic Models Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor. Logistic Regression,Logit Models,Models, Logistic,Logistic Model,Logistic Regressions,Logit Model,Model, Logistic,Model, Logit,Models, Logit,Regression, Logistic,Regressions, Logistic

Related Publications

P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0.
November 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
June 1994, Clinical pharmacology and therapeutics,
P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers.
November 2013, Journal of thrombosis and haemostasis : JTH,
P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
Recombinant factor VIIa.
January 2004, Emergency medicine Australasia : EMA,
P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
Recombinant Factor VIIA.
January 2009, Medical journal, Armed Forces India,
P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
Recombinant Factor VIIa.
July 1999, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
Clinical experience with recombinant factor VIIa.
March 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
Experiences with recombinant factor VIIa in haemophiliacs.
January 1991, Current studies in hematology and blood transfusion,
P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
Treatment of factor VII deficiency with recombinant factor VIIa.
January 1996, Haemostasis,
P Girard, and P Nony, and E Erhardtsen, and S Delair, and P Ffrench, and M Dechavanne, and J P Boissel
Thrombosis and recombinant factor VIIa.
October 2004, Journal of thrombosis and haemostasis : JTH,
Copied contents to your clipboard!